Emotion and Motivation in Patients With Psychosis

Not Applicable

Terminated

• Conditions: Schizophrenia

• Registration Number: NCT02853019
• Lead Sponsor: University Hospital, Strasbourg, France

Brief Summary

Anhedonia and avolition reflect emotional and motivational disorders, respectively. However, if these disorders play a major role in the symptomatology of schizophrenia, their mechanisms remain poorly understood, and existing treatments are inefficient on these symptoms. The literature suggests that the impairment does not concern emotion or motivation per se, but rather their influence on cognition. This project aims at using recent advances in the fundamental domain to better understand the cognitive and neuronal mechanisms of the patients' alterations, and especially how emotion and motivation influence cognition in schizophrenia.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-05-23
• Study First Submitted QC: 2016-07-28
• Study First Posted: 2016-08-02
• Study Start: 2017-02-02
• Status Verified: 2024-08
• Primary Completion: 2025-06-01
• Study Completion: 2025-06-01
• Last Update Submitted: 2025-08-18
• Last Update Posted: 2025-08-19

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 41

Inclusion Criteria

• diagnostic and Statistical Manual of Mental Disorders criteria for schizophrenia

Exclusion Criteria

• addiction problem
• invalidating visual sensory problems
• neurological history
• for the healthy volunteers: psychiatric history

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Change in the amplitude of the CNV (Contingent Negative Variation) as a function of the primer displayed on the screen	During EEG sessions, at experimental session 1 (Day 0) and experimental session 2 (up to Day 120)	Before each cognitive trial a primer will be displayed, which will be either neutral or convey emotion or motivation. The investigators will check whether this primer affects the subjects preparation by measuring the CNV, which is an evoked potential recorded with electroencephalography, and indexing preparatory effort.

Secondary Outcome Measures

Name	Time	Method
Change in the amplitude of the LPP (Late Positive Potential) as a function of the primer displayed on the screen	During EEG sessions, at experimental session 1 (Day 0) and experimental session 2 (up to Day 120)	The investigators will check whether primers affect the subjects attention by measuring the LPP, which is an evoked potential recorded with electroencephalography, and indexing sustained attention.

Trial Locations

Locations (1)

Unité INSERM 1114; 🇫🇷 Strasbourg, France